Braun Stacey Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-323,077
| Closed | -$15M | – | 115 |
|
|
2025
Q2 | $15M | Sell |
323,077
-24,206
| -7% | -$1.19M | 0.54% | 77 |
|
|
2025
Q1 | $21.2M | Sell |
347,283
-1,235
| -0.4% | -$72K | 0.87% | 52 |
|
|
2024
Q4 | $19.7M | Buy |
+348,518
| New | +$19.5M | 0.74% | 54 |
|
|
2021
Q4 | – | Sell |
-312,770
| Closed | -$18.5M | – | 134 |
|
|
2021
Q3 | $18.5M | Sell |
312,770
-9,597
| -3% | -$632K | 0.74% | 65 |
|
|
2021
Q2 | $21.5M | Sell |
322,367
-3,295
| -1% | -$215K | 0.84% | 51 |
|
|
2021
Q1 | $20.6M | Buy |
325,662
+5,216
| +2% | +$325K | 0.87% | 49 |
|
|
2020
Q4 | $19.9M | Buy |
320,446
+7,281
| +2% | +$448K | 0.89% | 48 |
|
|
2020
Q3 | $18.9M | Buy |
313,165
+430
| +0.1% | +$25.9K | 1.01% | 29 |
|
|
2020
Q2 | $18.4M | Buy |
312,735
+7,544
| +2% | +$451K | 1.06% | 25 |
|
|
2020
Q1 | $17M | Sell |
305,191
-6,554
| -2% | -$401K | 1.3% | 13 |
|
|
2019
Q4 | $20M | Buy |
+311,745
| New | +$17.9M | 1.11% | 18 |
|
|
2017
Q3 | – | Sell |
-6,590
| Closed | -$367K | – | 127 |
|
|
2017
Q2 | $367K | Sell |
6,590
-11,470
| -64% | -$624K | 0.02% | 129 |
|
|
2017
Q1 | $982K | Sell |
18,060
-127,542
| -88% | -$7M | 0.06% | 120 |
|
|
2016
Q4 | $8.51M | Sell |
145,602
-29,790
| -17% | -$1.63M | 0.56% | 88 |
|
|
2016
Q3 | $9.46M | Sell |
175,392
-86,392
| -33% | -$5.55M | 0.6% | 84 |
|
|
2016
Q2 | $19.3M | Sell |
261,784
-17,395
| -6% | -$1.23M | 1.25% | 12 |
|
|
2016
Q1 | $17.8M | Sell |
279,179
-42,691
| -13% | -$2.69M | 1.16% | 17 |
|
|
2015
Q4 | $22.1M | Buy |
321,870
+33,550
| +12% | +$2.22M | 1.39% | 5 |
|
|
2015
Q3 | $17.1M | Buy |
288,320
+39,785
| +16% | +$2.52M | 1.15% | 28 |
|
|
2015
Q2 | $16.5M | Buy |
248,535
+229,825
| +1,228% | +$15.1M | 0.7% | 69 |
|
|
2015
Q1 | $1.21M | Buy |
18,710
+10,955
| +141% | +$686K | 0.07% | 107 |
|
|
2014
Q4 | $458K | Buy |
7,755
+2,055
| +36% | +$116K | 0.03% | 120 |
|
|
2014
Q3 | $292K | Hold |
5,700
| – | – | 0.02% | 144 |
|
|
2014
Q2 | $277K | Buy |
5,700
+1,100
| +24% | +$54.2K | 0.02% | 143 |
|
|
2014
Q1 | $239K | Buy |
4,600
+300
| +7% | +$16K | 0.01% | 141 |
|
|
2013
Q4 | $229K | Buy |
+4,300
| New | +$219K | 0.01% | 137 |
|
|
2013
Q3 | – | Sell |
-8,550
| Closed | -$382K | – | 150 |
|
|
2013
Q2 | $382K | Buy |
+8,550
| New | +$371K | 0.02% | 125 |
|
Other funds holding BMY
Braun Stacey Associates's BMY Position: Q3 2025 in Review
Braun Stacey Associates sold out of Bristol-Myers Squibb (BMY) in Q3 2025, closing a stake of 323,077 shares — an estimated $15M sold.
Braun Stacey Associates first reported a position in BMY in Q2 2013 and held it in 27 quarters. The position peaked at $22.1M in Q4 2015. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Braun Stacey Associates reported no remaining Bristol-Myers Squibb position as of Q3 2025 after selling out during the quarter.
- Braun Stacey Associates sold 323,077 Bristol-Myers Squibb shares in Q3 2025, an estimated $15M.
- Braun Stacey Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 27 quarters.
- Braun Stacey Associates's Bristol-Myers Squibb position peaked at $22.1M in Q4 2015.
- 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Braun Stacey Associates's 13F filing for Q3 2025, filed 21 Oct 2025.